Farrell Rachel A, Giovannoni Gavin
Department of Neuroimmunology, Institute of Neurology, London, UK.
Mult Scler. 2007 Jun;13(5):567-77. doi: 10.1177/1352458506073522. Epub 2007 Feb 16.
Interferon Beta is well established as a first line agent to treat relapsing remitting Multiple Sclerosis. It frequently induces the formation of neutralising anti-Interferon Beta Antibodies (Nabs) which may abrogate the clinical efficacy of the drug. Numerous studies have shown a loss of bioactivity of the drug in the presence of Nabs. The focus has shifted to reliable quantification of Nabs and their appropriate incorporation into clinical practice. Here we review the development and persistence of Nabs, the effect on Interferon beta bioactivity, clinical and para-clinical autocome measures in trials, Nab assays and discuss management strategies to optimise the use of Interferon beta in relapsing remitting MS.
β-干扰素作为治疗复发缓解型多发性硬化症的一线药物已得到广泛认可。它经常诱导中和性抗β-干扰素抗体（Nabs）的形成，这可能会消除该药物的临床疗效。大量研究表明，在存在Nabs的情况下，药物的生物活性会丧失。目前的重点已转向对Nabs进行可靠的定量分析，并将其合理纳入临床实践。在此，我们回顾了Nabs的产生和持续存在情况、对β-干扰素生物活性的影响、试验中的临床和准临床自动结果测量、Nab检测方法，并讨论了优化β-干扰素在复发缓解型多发性硬化症中使用的管理策略。
